ad image

Company Info

Arranta Bio

Arranta Bio

CDMO

Overview

Founded in 2019, Arranta Bio is a visionary contract development and manufacturing organization (CDMO) that partners with companies seeking to develop and manufacture complex biological drugs and innovative therapies. Our dedicated team, state-of-the-art facilities, and unparalleled resources are crucial for advancing products from development to commercial launch. Arranta Bio continues to expand capacity and development and manufacturing services across multiple sites with technology platforms designed to meet the evolving demands of our clients and partners.
Arranta Bio
Contributions
20 Contributions1 / 1
Presenting an Integrated Solution for mRNA Vaccine Manufacturing
mRNA Vaccine Manufacturing

Presenting an Integrated Solution for mRNA Vaccine Manufacturing

Mark Bamforth; Dave Stevens

Arranta Bio

PAO-01-22-R250-04Jan 26, 2022
Serving an Accelerated Market with mRNA Production
mRNA Manufacturing

Serving an Accelerated Market with mRNA Production

Mark Bamforth

Arranta Bio

PAO-11-21-CL-06Dec 08, 2021
Investing in mRNA Production

Investing in mRNA Production

Michael Wourms

Arranta Bio

PA766Nov 22, 2021
Limiting Risk In mRNA Development and Production
mRNA Manufacturing

Limiting Risk In mRNA Development and Production

Doug Kennedy

Arranta Bio

PAO-11-21-CL-05Nov 22, 2021
Integrating a Fragmented mRNA Supply Chain
mRNA Manufacturing

Integrating a Fragmented mRNA Supply Chain

Dave Stevens

Arranta Bio

PAO-11-21-CL-04Nov 22, 2021
Arranta Bio
Sale

Arranta Bio Announces Completion of Sale of Florida Site and Progress on $150M Investment Plan to Expand Development and Commercial Manufacturing Services

Arranta Bio

PA775Nov 16, 2021
Integrated Support Facilitates mRNA Product Development and Commercialization
mRNA

Integrated Support Facilitates mRNA Product Development and Commercialization

Michael Wourms; Dave Stevens

Arranta Bio

PAO-10-21-CL-15Oct 26, 2021
Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives
Live Biotherapeutic Products

Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives

Aaron B. Cowley, Ph.D.; Nicole O'Brien, Ph.D.

ReciBioPharm

PAO-09-21-CL-11Sep 28, 2021
Arranta Bio
mRNA Vaccines

Arranta Bio Announces First End-to-End Manufacturing for mRNA Vaccines in its Commercial-Ready GMP Facility

Arranta Bio

PR-M09-21-05Sep 23, 2021
Framing the Narrative on CMC Development for Microbiome Therapeutics
Live Biotherapeutic Products

Framing the Narrative on CMC Development for Microbiome Therapeutics

Aaron B. Cowley, Ph.D.; Melanie Cerullo; Jeff Heiser

ReciBioPharm

PAO-06-21-CL-05Jun 14, 2021
Arranta Bio
Manufacturing Facility

Arranta Bio Announces Addition of 130,000 sq. ft. Boxborough, Mass., Manufacturing Facility to Supply Clinical and Commercial Microbiome Products for Clients and Closes Series B Equity Financing

Arranta Bio

PR-M03-21-002-1066Mar 08, 2021
Life Imitating Science: Arranta Bio’s Commitment to Corporate Social Responsibility and Diversity
Corporate Social Responsibility

Life Imitating Science: Arranta Bio’s Commitment to Corporate Social Responsibility and Diversity

Susan Surabian; Melanie Cerullo

Arranta Bio

PAP-Q4-20-CL-002Dec 09, 2020
How Does Arranta Bio Envision the Future of the Pharma/Biopharma Industry?
The Future of Healthcare

How Does Arranta Bio Envision the Future of the Pharma/Biopharma Industry?

Arranta Bio

PAP-Q4-20-RT2-007Dec 09, 2020
How Is Arranta Bio Evolving its Business Model to Meet the Future of Healthcare?
The Future of Healthcare

How Is Arranta Bio Evolving its Business Model to Meet the Future of Healthcare?

Arranta Bio

PAP-Q3-20-RT2-009Sep 29, 2020
Arranta Bio
Capacity Expansion

Arranta Bio Announces Mechanical Completion of Commercial-Ready Capacity for Advanced Biologics

Arranta Bio

PR-M09-20-30Sep 28, 2020
Selecting a Microbiome CDMO Partner for the Long Term
Microbiome

Selecting a Microbiome CDMO Partner for the Long Term

Dave Stevens; Jason Rahal

Arranta Bio

PAP-Q2-20-CL-008Jul 01, 2020
How is Arranta Bio Preparing to Face the Future of Healthcare?
Future of Healthcare

How is Arranta Bio Preparing to Face the Future of Healthcare?

Arranta Bio

PAP-Q1-20-R2-005Mar 19, 2020
Supporting Commercialization of Live Biotherapeutic Products for Microbiome-Based Therapies
Microbiome

Supporting Commercialization of Live Biotherapeutic Products for Microbiome-Based Therapies

Mark Bamforth

Arranta Bio

PAP-Q4-19-CL-009Dec 06, 2019
Arranta Bio
Funding

Arranta Bio Announces $82M in New Funding, and a Strategic Partnership with Thermo Fisher Scientific

Arranta Bio

PR-M10-19-NI-044Oct 30, 2019
Ensuring Confidence in Viral Vector Manufacturing
Viral Vector

Ensuring Confidence in Viral Vector Manufacturing

Michael Wourms; Christopher K. Murphy

Arranta Bio

PAP-Q1-18-CL-012Mar 12, 2018
1 / 1